Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future

L. Voncina, B. B. Godman, V. Vlahovic-Palcevski, M. Bennie, I. Bishop

Research output: Contribution to journalConference Contribution

6 Citations (Scopus)

Abstract

Renin - angiotensin (RA) drugs (Angiotensin Converting Enzyme Inhibitors - ACEIs - and Angiotensin Receptor Blockers - ARBs) are accepted treatments for hypertension and Congestive Heart Failure. Coughing can occur with ACEIs leading to development of ARBs. Trials showed though discontinuation due to coughing in a minority of patients on ACEIs (2- - 3%). ARB prescribing restrictions in Austria as higher costs than ACEIs moderated utilisation. Other demand side measures in Spain (Catalonia) following generic ACEIs also moderated ARB utilisation.

Fingerprint

Austria
Angiotensin Receptor Antagonists
Angiotensins
Angiotensin-Converting Enzyme Inhibitors
Renin
Spain
Heart Failure
Hypertension
Costs and Cost Analysis
Pharmaceutical Preparations
Therapeutics

Keywords

  • receptor blockers
  • drug utilisation
  • Croatia

Cite this

Voncina, L. ; Godman, B. B. ; Vlahovic-Palcevski, V. ; Bennie, M. ; Bishop, I. / Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future. In: Pharmacoepidemiology and Drug Safety. 2011 ; Vol. 20, No. Suppl.1. pp. S210-S210.
@article{9a87e9e22b0d45d39a96b862fc17a732,
title = "Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future",
abstract = "Renin - angiotensin (RA) drugs (Angiotensin Converting Enzyme Inhibitors - ACEIs - and Angiotensin Receptor Blockers - ARBs) are accepted treatments for hypertension and Congestive Heart Failure. Coughing can occur with ACEIs leading to development of ARBs. Trials showed though discontinuation due to coughing in a minority of patients on ACEIs (2- - 3{\%}). ARB prescribing restrictions in Austria as higher costs than ACEIs moderated utilisation. Other demand side measures in Spain (Catalonia) following generic ACEIs also moderated ARB utilisation.",
keywords = "receptor blockers, drug utilisation, Croatia",
author = "L. Voncina and Godman, {B. B.} and V. Vlahovic-Palcevski and M. Bennie and I. Bishop",
year = "2011",
doi = "10.1002/pds.2206",
language = "English",
volume = "20",
pages = "S210--S210",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
number = "Suppl.1",

}

Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future. / Voncina, L.; Godman, B. B.; Vlahovic-Palcevski, V.; Bennie, M.; Bishop, I.

In: Pharmacoepidemiology and Drug Safety, Vol. 20, No. Suppl.1, 482, 2011, p. S210-S210.

Research output: Contribution to journalConference Contribution

TY - JOUR

T1 - Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future

AU - Voncina, L.

AU - Godman, B. B.

AU - Vlahovic-Palcevski, V.

AU - Bennie, M.

AU - Bishop, I.

PY - 2011

Y1 - 2011

N2 - Renin - angiotensin (RA) drugs (Angiotensin Converting Enzyme Inhibitors - ACEIs - and Angiotensin Receptor Blockers - ARBs) are accepted treatments for hypertension and Congestive Heart Failure. Coughing can occur with ACEIs leading to development of ARBs. Trials showed though discontinuation due to coughing in a minority of patients on ACEIs (2- - 3%). ARB prescribing restrictions in Austria as higher costs than ACEIs moderated utilisation. Other demand side measures in Spain (Catalonia) following generic ACEIs also moderated ARB utilisation.

AB - Renin - angiotensin (RA) drugs (Angiotensin Converting Enzyme Inhibitors - ACEIs - and Angiotensin Receptor Blockers - ARBs) are accepted treatments for hypertension and Congestive Heart Failure. Coughing can occur with ACEIs leading to development of ARBs. Trials showed though discontinuation due to coughing in a minority of patients on ACEIs (2- - 3%). ARB prescribing restrictions in Austria as higher costs than ACEIs moderated utilisation. Other demand side measures in Spain (Catalonia) following generic ACEIs also moderated ARB utilisation.

KW - receptor blockers

KW - drug utilisation

KW - Croatia

U2 - 10.1002/pds.2206

DO - 10.1002/pds.2206

M3 - Conference Contribution

VL - 20

SP - S210-S210

JO - Pharmacoepidemiology and Drug Safety

T2 - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - Suppl.1

M1 - 482

ER -